Regeneron Pharmaceuticals, Inc. $REGN is Mcdonald Capital Investors Inc. CA’s 2nd Largest Position

Mcdonald Capital Investors Inc. CA lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 205,871 shares of the biopharmaceutical company’s stock after selling 2,370 shares during the quarter. Regeneron Pharmaceuticals accounts for 10.9% of Mcdonald Capital Investors Inc. CA’s holdings, making the stock its 2nd largest holding. Mcdonald Capital Investors Inc. CA’s holdings in Regeneron Pharmaceuticals were worth $159,064,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Principal Financial Group Inc. lifted its position in Regeneron Pharmaceuticals by 0.7% in the first quarter. Principal Financial Group Inc. now owns 120,425 shares of the biopharmaceutical company’s stock valued at $93,045,000 after buying an additional 800 shares during the last quarter. Chicago Partners Investment Group LLC increased its position in shares of Regeneron Pharmaceuticals by 48.8% during the first quarter. Chicago Partners Investment Group LLC now owns 2,001 shares of the biopharmaceutical company’s stock valued at $1,494,000 after acquiring an additional 656 shares during the last quarter. Procyon Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 102.0% in the 1st quarter. Procyon Advisors LLC now owns 889 shares of the biopharmaceutical company’s stock valued at $687,000 after acquiring an additional 449 shares during the period. Citizens Financial Group Inc. RI raised its stake in shares of Regeneron Pharmaceuticals by 23.7% in the 1st quarter. Citizens Financial Group Inc. RI now owns 4,775 shares of the biopharmaceutical company’s stock valued at $3,689,000 after acquiring an additional 916 shares during the period. Finally, Fifth Third Bancorp lifted its holdings in shares of Regeneron Pharmaceuticals by 126.3% in the 1st quarter. Fifth Third Bancorp now owns 34,910 shares of the biopharmaceutical company’s stock worth $26,973,000 after acquiring an additional 19,485 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $663.09 on Tuesday. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $821.11. The firm has a market cap of $70.10 billion, a PE ratio of 16.16, a price-to-earnings-growth ratio of 1.47 and a beta of 0.24. The company’s 50 day moving average is $644.42 and its two-hundred day moving average is $721.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. During the same quarter in the previous year, the firm posted $8.22 earnings per share. The company’s quarterly revenue was up 19.0% compared to the same quarter last year. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This trade represents a 1.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of research analyst reports. Piper Sandler lowered their price objective on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a research report on Thursday, July 9th. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $778.00 to $769.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. Guggenheim raised their price target on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a research report on Friday, May 1st. HSBC dropped their price objective on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research note on Monday, July 6th. Finally, Wall Street Zen lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $787.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.